tetano
Editor, Senior Moderator
J Cell Immunol
. 2021;3(2):68-77.
doi: 10.33696/immunology.3.080.
Review of the COVID-19 Risk in Multiple Sclerosis
Farhan Chaudhry[SUP] 1 2 [/SUP], Cristina Jageka[SUP] 2 [/SUP], Phillip D Levy[SUP] 1 [/SUP], Mirela Cerghet[SUP] 2 3 [/SUP], Robert P Lisak[SUP] 3 4 [/SUP]
Affiliations
Abstract
The ongoing pandemic of the novel coronavirus of 2019 (COVID-19) has resulted in over 1 million deaths, primarily affecting older patients with chronic ailments. Multiple sclerosis (MS) patients have been deemed particularly vulnerable given their high rates of disability and increased susceptibility to infections. There have also been concerns regarding disease-modifying therapy (DMT) during the pandemic as many DMTs may increase the risk of infection due to some of their immunosuppressive properties. Furthermore, due to MS-related chronic inflammatory damage within the central nervous system, there have been concerns for worsening neurological injury by COVID-19. This has resulted in an alarmingly high level of anxiety and stress among the MS community leading to a lack of compliance with medications and routine check-ups, and even failure to obtain treatment for relapse. However, there is currently substantial evidence that MS and most DMT usage is not associated with increased COVID-19 severity. MS patients who suffer worse outcomes were more likely to be older and suffer from significant disabilities and comorbid conditions, which would also be expected from those in the general population. Likewise, there is little if any evidence demonstrating an increased susceptibility of MS patients to COVID-19-related neurological complications. Therefore, we aim to summarize the most recent findings related to COVID-19 and MS demonstrating that MS and most DMTs do not appear as risk factors for severe COVID-19.
. 2021;3(2):68-77.
doi: 10.33696/immunology.3.080.
Review of the COVID-19 Risk in Multiple Sclerosis
Farhan Chaudhry[SUP] 1 2 [/SUP], Cristina Jageka[SUP] 2 [/SUP], Phillip D Levy[SUP] 1 [/SUP], Mirela Cerghet[SUP] 2 3 [/SUP], Robert P Lisak[SUP] 3 4 [/SUP]
Affiliations
- PMID: 33959727
- PMCID: PMC8098748
- DOI: 10.33696/immunology.3.080
Abstract
The ongoing pandemic of the novel coronavirus of 2019 (COVID-19) has resulted in over 1 million deaths, primarily affecting older patients with chronic ailments. Multiple sclerosis (MS) patients have been deemed particularly vulnerable given their high rates of disability and increased susceptibility to infections. There have also been concerns regarding disease-modifying therapy (DMT) during the pandemic as many DMTs may increase the risk of infection due to some of their immunosuppressive properties. Furthermore, due to MS-related chronic inflammatory damage within the central nervous system, there have been concerns for worsening neurological injury by COVID-19. This has resulted in an alarmingly high level of anxiety and stress among the MS community leading to a lack of compliance with medications and routine check-ups, and even failure to obtain treatment for relapse. However, there is currently substantial evidence that MS and most DMT usage is not associated with increased COVID-19 severity. MS patients who suffer worse outcomes were more likely to be older and suffer from significant disabilities and comorbid conditions, which would also be expected from those in the general population. Likewise, there is little if any evidence demonstrating an increased susceptibility of MS patients to COVID-19-related neurological complications. Therefore, we aim to summarize the most recent findings related to COVID-19 and MS demonstrating that MS and most DMTs do not appear as risk factors for severe COVID-19.